{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:01:21Z","timestamp":1790128881605,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejca.2020.04.028","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T23:08:06Z","timestamp":1591916886000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy"],"prefix":"10.1016","volume":"135","author":[{"given":"Romain","family":"Carron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Amatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausicaa","family":"Malissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-3766","authenticated-orcid":false,"given":"Anne","family":"Balossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Loundou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Muracciole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"R\u00e9gis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.028_bib1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","article-title":"Clinical management of multiple melanoma brain metastases: a systematic review","volume":"1","author":"Goyal","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.028_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","article-title":"Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases","volume":"28","author":"Nardin","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.04.028_bib6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjc.2017.142","article-title":"Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases","volume":"116","author":"Parakh","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2020.04.028_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/pcmr.12682","article-title":"Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy","volume":"31","author":"Tio","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.04.028_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","article-title":"Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity","volume":"7","author":"Minniti","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2020.04.028_bib9","article-title":"Effect of Gamma knife radiosurgery and programmed cell death 1 receptor antagonists on metastatic melanoma","volume":"9","author":"Nordmann","year":"2017","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.028_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COC.0000000000000509","article-title":"Concurrent radiosurgery and immune checkpoint inhibition: improving regional intracranial control for patients with metastatic melanoma","volume":"42","author":"Murphy","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib12","first-page":"30053","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"S1470\u20132045","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.04.028_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.04.028_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Efficacy and safety of Nivolumab plus ipilimumab in patients with melanoma metastatic to the brain: results of the phase II study checkmate 204. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.028_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2017.07.017","article-title":"Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery","volume":"84","author":"Gaudy-Marqueste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.028_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2013.05.002","article-title":"Stereotactic radiosurgery in the treatment of brain metastases: the current evidence","volume":"40","author":"Lippitz","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2020.04.028_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000331191","article-title":"Stereotactic radiosurgery of brain metastasis from melanoma","volume":"25","author":"Marchan","year":"2012","journal-title":"Prog Neurol Surg"},{"key":"10.1016\/j.ejca.2020.04.028_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2016.06.003","article-title":"Radiotherapy and immune checkpoints inhibitors for advanced melanoma","volume":"120","author":"Filippi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2006.01.024","article-title":"Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy","volume":"65","author":"Gaudy-Marqueste","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejca.2020.04.028_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1227\/01.NEU.0000333263.31870.31","article-title":"Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study","volume":"63","author":"Dequesada","year":"2008","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.028_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02688699943655","article-title":"Stereotactic radiosurgery, VIII: the classification of postradiation reactions","volume":"13","author":"Plowman","year":"1999","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.ejca.2020.04.028_bib25","first-page":"160","article-title":"Differentiating radiation effect from tumor progression after stereotactic radiosurgery: T1\/T2 matching","volume":"57","author":"Kano","year":"2010","journal-title":"Clin Neurosurg"},{"key":"10.1016\/j.ejca.2020.04.028_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2020.04.028_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1507669","article-title":"Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma","volume":"8","author":"Pfannenstiel","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2020.04.028_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","article-title":"Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases","volume":"110","author":"Rauschenberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.028_bib29","first-page":"1","article-title":"Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects","volume":"5","author":"Diao","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.04.028_bib30","first-page":"417913","article-title":"Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients","author":"Du Four","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ejca.2020.04.028_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.04.028_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-014-1617-9","article-title":"Ipilimumab and whole brain radiation therapy for melanoma brain metastases","volume":"121","author":"Gerber","year":"2015","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.04.028_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.028_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-017-2470-4","article-title":"Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma","volume":"133","author":"Fang","year":"2017","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article","volume":"114","author":"Liew","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.04.028_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2020.04.028_bib39","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2020.04.028_bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.ejca.2020.04.028_bib41","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.04.028_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz046","article-title":"The Impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:29Z","timestamp":1760732849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"alternative-id":["S0959804920302318"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}